Fig. 1From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort studyMean levels of tenascin-C in healthy controls and patients with systemic lupus erythematosus with low [Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) <6] and high (SLEDAI-2 K ≥6) disease activityBack to article page